These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21465665)

  • 1. Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria.
    Pajor G; Somogyi L; Melegh B; Alpar D; Kajtar B; Farkas L; Kneif M; Bollmann D; Pajor L; Sule N
    Cytometry A; 2011 May; 79(5):375-82. PubMed ID: 21465665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.
    Huysentruyt CJ; Baldewijns MM; Rüland AM; Tonk RJ; Vervoort PS; Smits KM; van de Beek C; Speel EJ
    Histopathology; 2011 Jun; 58(7):1048-53. PubMed ID: 21707706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.
    Hajdinjak T
    Urol Oncol; 2008; 26(6):646-51. PubMed ID: 18367109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
    Asali MG; Kaneti J; Manor E
    Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer.
    Gofrit ON; Zorn KC; Silvestre J; Shalhav AL; Zagaja GP; Msezane LP; Steinberg GD
    Urol Oncol; 2008; 26(3):246-9. PubMed ID: 18452813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vysis UroVysion for the detection of urothelial carcinoma.
    Halling KC
    Expert Rev Mol Diagn; 2003 Jul; 3(4):507-19. PubMed ID: 12877389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients.
    Chuang KL; Chuang HC; Ng KF; Chang YH; Wu CT; Chuang CK; Liao SK; Pang ST
    BJU Int; 2010 May; 105(10):1413-6. PubMed ID: 19818076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer detection using FISH (UroVysion assay).
    Halling KC; Kipp BR
    Adv Anat Pathol; 2008 Sep; 15(5):279-86. PubMed ID: 18724101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma - FISHing for the right catch.
    Bubendorf L
    Acta Cytol; 2011; 55(2):113-9. PubMed ID: 21325794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased efficiency of detecting genetically aberrant cells by UroVysion test on voided urine specimens using automated immunophenotypical preselection of uroepithelial cells.
    Pajor G; Sule N; Alpar D; Kajtar B; Kneif M; Bollmann D; Somogyi L; Pajor L
    Cytometry A; 2008 Mar; 73(3):259-65. PubMed ID: 18228559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
    Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
    J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
    Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
    Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.
    Laudadio J; Keane TE; Reeves HM; Savage SJ; Hoda RS; Lage JM; Wolff DJ
    BJU Int; 2005 Dec; 96(9):1280-5. PubMed ID: 16287445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.